Immune Design Announces Multiple Presentations at CTOS and SITC Highlighting the Breadth of Existing & Future Product Candida...
November 07 2017 - 8:00AM
Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company
focused on oncology, today announced seven presentations at the
upcoming Connective Tissue Oncology Society (CTOS) and the Society
for Immunotherapy of Cancer (SITC) Annual Meetings to be held in
Maui, Hawaii from November 8-11 and in National Harbor, Maryland,
from November 8-12, 2017 respectively.
Selected highlights from these presentations
include:
CTOS
A Phase 2 study of CMB305 and Atezolizumab in NY-ESO-1+
soft tissue sarcoma: interim analysis of immunogenicity, tumor
control and survival (Abstract ID #2785040, Presenter:
Sant P. Chawla, M.D, Director of the Cancer Center of Southern
California, medical oncologist at Cedars-Sinai Comprehensive Cancer
Center, adjunct associate professor at Stanford University and the
University of Texas, M.D. Anderson Cancer Center; Encore
Presentation)
- Interim analysis (n=36) in the randomized Phase 2 study showed
patients receiving the combination of CMB305 and atezolizumab
experienced greater clinical benefit and immune response than those
who received atezolizumab alone, notwithstanding that patients in
the combination arm had more advanced disease.
- The trend of greater clinical benefit on the combination arm
remained consistent in the full study population (n=88), including
partial responses on the combination arm and none on the
atezolizumab-only arm.
Association of NY-ESO-1 expression with
baseline immunity and clinical outcomes in soft tissue sarcoma
patients treated with LV305 or CMB305 (Abstract ID
#2804760, Presenter: Seth M. Pollack, M.D, Fred Hutchinson Cancer
Research Center, Assistant Professor, Division of Oncology,
University of Washington)
- The cancer-testes antigen, NY-ESO-1, is highly expressed in
certain soft tissue sarcoma subtypes. 48 soft tissue sarcoma
patients receiving the NY-ESO-1-target cancer vaccine, CMB305 or
its prime-only component, LV305, were pooled for analysis.
- Despite a poorer prognosis expected in patients with tumors
with high levels of NY-ESO-1 expression, patients with high
expression levels treated with either LV305 or CMB305 had a trend
toward improved clinical outcomes as compared to those in the lower
quartiles.
SITC
Anti-NY-ESO-1 immune response and
survival benefit after LV305 therapy in patients with advanced
sarcoma and other solid tumors (Poster #P109, Presenter:
Jan H. ter Meulen, M.D., Dr. Habil., DTM&H, Immune
Design)
- Immune response and long term overall survival data in 24
sarcoma patients, who have received multiple lines of therapy and
have been followed for at least two years, shows a median
progression free survival of 4.67 months and a median overall
survival that has not yet been reached.
- Exploratory analysis of biomarker data demonstrates that
patients with baseline anti-NY-ESO-1 antibodies or induced immune
response on LV305 appear to have improved survival outcomes.
G100 and ZVex®-based combination
immunotherapy induces near complete regression of established
glioma tumors in mice (Poster #P256, Presenter: Tina Chang
Albershardt, Ph.D., Immune Design)
- “Prime/pull” immunization consisting of systemic administration
of ZVex vector with-antigen and intratumoral administration of
G100, respectively, resulting in a >90% reduction of
established gliomas.
- We believe these are among the best data showing control of
glioma in the orthotopic mouse model using therapeutic cancer
vaccines.
Transduction of MAGE-A1, A3, A4, A10 and
IL-12 by ZVex®, a dendritic cell targeting platform induces robust
multi-antigen T-cell immune responses without antigenic
interference or immunodominance (Poster #P127, Presenter:
Jardin Leleux, Ph.D., Immune Design)
- A multigenome ZVex vector expressing the cancer testis
antigens MAGE-A1, 3, 4, 10 and the cytokine IL12 induces
balanced T-cell responses against all four antigens.
- These data demonstrate that the multigenome vector
platform can overcome antigenic competition, a common problem
encountered with virally vectored vaccines.
Intratumoral expression of IL12 using
the ZVex® dendritic cell-targeting lentiviral vector exerts potent
anti-tumor effects via induction of multiple immune effectors,
including CD8 T cell responses (Poster #P401, Presenter:
Tina Chang Albershardt, Ph.D., Immune Design)
- Extending previously published observations, these data show
that the potent intratumoral effects of ZVex-IL12 are mediated
by multiple immune effector cells, including CD8 T-cells.
- These data provide further preclinical validation of the
vector platform for intratumoral applications.
Public NY-ESO-1 specific TCRs as novel
biomarkers for immune monitoring of NY-ESO-1 positive cancer
patients (Poster #P58 and oral presentation, presenter:
Hailing Lu, M.D., Ph.D., Immune Design)
- These data extend previously published observations of an
association of NY-ESO-1- specific, shared TCR Vβ-CD3 sequences with
survival in NY-ESO-1-expressing cancer patients.
- The findings may support use of public TCR as a vaccine
response biomarker for NY-ESO-1 cancer patients that
could augment or replace established, yet more cumbersome, T-cell
ELISPOT assays.
About Immune Design
Immune Design is a clinical-stage immunotherapy
company employing next-generation in vivo approaches to enable the
body's immune system to fight disease. The company's technologies
are engineered to activate the immune system's natural ability to
generate and/or expand antigen-specific cytotoxic T cells, while
also enhancing other immune effectors, to fight cancer and other
chronic diseases. CMB305 and G100, the two leading product
candidates focused in cancer immunotherapy, are the first products
from Immune Design’s two separate discovery platforms targeting
dendritic cells in vivo, ZVex® and GLAAS®. Both ZVex and
GLAAS also have potential applications in infectious disease and
allergy as demonstrated by ongoing pharmaceutical
collaborations. Immune Design has offices in Seattle and
South San Francisco. For more information, please visit
www.immunedesign.com.
Cautionary Note on Forward-Looking
Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Words such as "may," "will," "expect," "plan,"
"intend", "believe", "appear", "trend" and similar expressions (as
well as other words or expressions referencing future events,
conditions or circumstances) are intended to identify
forward-looking statements. These forward-looking statements are
based on Immune Design's expectations and assumptions as of the
date of this press release. Each of these forward-looking
statements involves risks and uncertainties. Actual results may
differ materially from these forward-looking statements.
Forward-looking statements contained in this press release include,
but are not limited to, statements about the timing, progress,
scope and outcome of preclinical studies and clinical trials, the
clinical application of Immune Design's product candidates and
technology platforms and the association of data with treatment
outcomes. Many factors may cause differences between current
expectations and actual results including unexpected safety or
efficacy data observed during preclinical or clinical studies.
Success in preclinical testing and early clinical trials does not
ensure that later clinical trials will be successful. Other factors
that may cause Immune Design's actual results to differ from those
expressed or implied in the forward-looking statements in this
press release are discussed in Immune Design's filings with the
U.S. Securities and Exchange Commission, including the "Risk
Factors" sections contained therein. Except as required by law,
Immune Design assumes no obligation to update any forward-looking
statements contained herein to reflect any change in expectations,
even as new information becomes available.
Media ContactJulie
RathbunRathbun Communicationsjulie@rathbuncomm.com206-769-9219
Investor ContactShari
AnnesAnnes Associatessannes@annesassociates.com650-888-0902
IMMUNE DESIGN CORP. (NASDAQ:IMDZ)
Historical Stock Chart
From Mar 2024 to Apr 2024
IMMUNE DESIGN CORP. (NASDAQ:IMDZ)
Historical Stock Chart
From Apr 2023 to Apr 2024